Wall Street brokerages predict that Prevail Therapeutics Inc. (NASDAQ:PRVL) will announce ($0.64) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Prevail Therapeutics’ earnings, with estimates ranging from ($0.65) to ($0.63). The company is scheduled to report its next quarterly earnings report on Tuesday, March 31st.
According to Zacks, analysts expect that Prevail Therapeutics will report full year earnings of ($2.88) per share for the current year, with EPS estimates ranging from ($3.55) to ($2.34). For the next year, analysts expect that the company will report earnings of ($2.77) per share, with EPS estimates ranging from ($3.15) to ($2.30). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Prevail Therapeutics.
A number of research analysts have recently weighed in on the stock. Citigroup assumed coverage on shares of Prevail Therapeutics in a research note on Thursday, March 5th. They set a “buy” rating and a $24.00 price objective for the company. Oppenheimer assumed coverage on shares of Prevail Therapeutics in a research note on Tuesday, February 18th. They set an “outperform” rating and a price objective for the company. BidaskClub cut shares of Prevail Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Wedbush reissued an “outperform” rating and set a $19.00 price objective (down from $20.00) on shares of Prevail Therapeutics in a research note on Thursday. Finally, Zacks Investment Research cut shares of Prevail Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 29th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $19.00.
Shares of PRVL opened at $12.00 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 17.05 and a quick ratio of 17.05. The firm has a 50 day simple moving average of $15.27 and a 200-day simple moving average of $14.19. Prevail Therapeutics has a 1-year low of $7.41 and a 1-year high of $19.25.
About Prevail Therapeutics
Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.
Further Reading: Why Invest in Dividend Achievers?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.